Dataset from A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease

This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled
study will evaluate the efficacy and safety of RO4602522 in participants with moderate
severity Alzheimer's disease. Participants who are taking background therapy of
acetylcholinesterase inhibitors (AChEI) alone or in combination with memantine for at least 4
months before screening will be randomized to receive either one of two doses of RO4602522 or
placebo for 12 months.